Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (10888)	7/23/1999 12:02:00 AM
From: aknahow	Read Replies (2) \| Respond to of 17367

Seriously, AGN has earnings, dividends, options, marginable and they will move BPI into clinic. While one is probably looking at five years minimum before anything gets developed, that might not be the case for a drug already approved with effectiveness proven when combined with a human protein that has already had a nice safety record. Could see the combination using less of the antibiotic and reducing side effects or using the current dosage looking for enhanced performance. I am going to continue to look at it. Are they un-blinding as we post? Did they un-blind when the stock sale was consummated? What did you think of the 150 deaths in the U.K?? Any thoughts on the SOC given the information you posted. You know when it is hard to get an appointment in your HMO, because the phone line is busy many times one ends up just not trying. I wonder what one does to get into one of the U.K hospitals early on before it is obvious your kid has meningococcemia? Bet it's a real mess. Feel lucky that we in the U.S. may eventually end up being able to find out everything that goes wrong. <g>